Clinical and laboratory characteristics of hospitalised patients with neurological manifestations of HIV/aids at the Nairobi Hospital

East African Medical Journal

Volumn 84, Issue 2, 2007, Pages 67-76

  Jowi, J O ^a   Mativo, P M ^b   Musoke, S S ^b  

^a KENYATTA NATIONAL HOSPITAL   (Kenya)

^b Nairobi Hospital   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AIDS RELATED COMPLEX; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CRYPTOCOCCAL MENINGITIS; ENCEPHALITIS; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MALE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TOXOPLASMOSIS; TUBERCULOUS MENINGITIS; VIROLOGY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CENTRAL NERVOUS SYSTEM DISEASES; CEREBROVASCULAR ACCIDENT; ENCEPHALITIS; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; KENYA; MALE; MENINGITIS, CRYPTOCOCCAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TOXOPLASMOSIS, CEREBRAL; TUBERCULOSIS, MENINGEAL;

EID: 34748924255     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Brack-Werner R. Astrocytes HIV cellular reservoirs and important participants in neuropat ho genesis. AIDS. 1999; 13:1-22.
2. Wiley C.A., Schrier R.D., Nelson J.A., et al. Cellular localisation of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc. Natl. Acad. Sci. USA. 1986; 83: 7089-7093.
3. Albright A.V., Soldan S.S. and Gonzalez-Scarano. Pathogenesis of human immunodeficiency virus- induced neurological disease.J. Neurovirol. 2003; 9: 222-227.
4. Gartner S. and Liu Y. Insights into the role of immune activation in HIV neuropathogenesis.J. Neurovirol. 2002; 8:69-165
5. Sharer L.R. Pathology of HIV infection of the central nervous system: A review. J. Neuropathol. Exp. Pathol. 1992;51:3-11.
6. Rausch D.M. and Davis M.R. HIV in the CNS: Pathogenenic relationships to systemic HIV disease and other CNS diseases.J. Neurivirol. 2001; 7: 85-96.
7. Bagasra O., Lavi E., Bobroski L., et al. Cellular reservoir of HIV in the central nervous system of infected individuals identification by the combination of in-situ polymerase chain reaction and immunochemistry. AIDS. 1990; 10:573-585.
8. Persidsky Y., Stins M., Way D., et al. A model for monocyte migration through the blood brain barrier during HIV encephalitis.J. Immunol. 1997; 158:3499-3510.
9. Brew B.J., Pemberton L., Cunningham P., et al. Levels of human immunodeficiency virus type 1 RNA in cerebral spinal fluid correlated with AIDS dementia stage.J. Infect. Dis. 1997; 175:963-966.
10. Sacktor N., Tarwater P.M., Skolasky R.L., et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurol. 2001a; 57:542-544.
11. Cysique L.A., Maruff P. and Brew B.J. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch. Neurol. 2004; 61:1699-1704.
12. Letendre S.L., McCutchan J.A., Childers M.E., et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann. Neurol. 2004; 56:416-423.
13. De Luca A., Ciancio B.C., Larussa D., et al. Correlates of independent HIV replication in the CNS and its control by antiretrovirals. Neurol. 2002; 59:342-347.
14. Portegies P., de Gans J., Lange J.M., et al. Declining incidence of AIDS dementia complex after introduction of Zidovudine treatment. Brit. Med. J. 1989; 299: 819-821.
15. Dalakas M.C., Ilia I., Pezeshpour G.H., et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 1990; 322: 1098-1105. (Pubitemid 20149526)
16. Morgellow S., Wolfe D., Godfrey E., et al. Mitochondrial abnormalities in HIVassociated myopathy. Acta. Neuropathol. 1995; 90:366-374.
17. Lichtenstein K.A., Armon C, Baron., et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin. Infect. Dis. 2005; 40:148-157.
18. Kolson D.L. Neuropathogenesis of central nervous system HIV-1 infection. Clin. Lab. Med. 2002; 22: 703-717.
19. Kaul M. and Lipiton S.A. Chemokines and activated macrophages in HIV gp 120-induced neural apoptosis. Proc. Natl. Acad. Sci. USA. 1999; 96:8212-8216.
20. Li W., Galey D., Mattson M.P. and Nath A. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox. Res. 2005; 8:119-134.
21. Nath A., Conant K., Chen P., et al. Transient exposure to HIV Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon.J. Biol. Chem. 1999; 274:17098-17102.
22. Patel C.A., Mukhtar M., Harley S., et al. Lentiviral expression of HIV Vpr induces apoptosis in human neurons.J. Neurovirol. 2002; 8:86-99.
23. Smith D.C., Guillemin G.J., Pemberton L., et al. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat.J. Neurovirol. 2001; 7:56-60
24. Jowi J.O. and Musoke S.S. Cerebral venous sinus thrombosis: a complication of HIV/AIDS: Report of three cases. Hlth. Line. 2004; 8:57-62.
25. Khosrow A., Frank J., Vakman Y., et al. Intracranial venous sinus thrombosis complicating AIDS associated nephropathy. AIDS Read. 2003; 13:143-148.
26. Berger J.R., Harris J.O. and Gregorios J. Cerebral vascular disease in AIDS: A case control study. AIDS. 1990; 4:239-244.
27. Kieburtz K.D., Eskin T.A. and Ketonen L. Opportunistic cerebral vasculopathy and stroke in patients with Acquired Immunodeficiency Syndrome. Arch. Neurol. 1993;50:430-432.
28. Bartlett J.G. The 2002 Abbreviated guide to the medical management of HIV infection PG John Hopkins University Press; 2002.
29. CDC. Classification system for human T-lymphotropic virus type 111/lymphadenopathy-associated virus infections. MMWR. 1986; 35:334.
30. CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR. 1987; 36: S1-S15.
31. Goedert J.J., Kessler CM., Aledort L.M., et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N. Engl. J. Med. 1989; 321: 1141-1148.
32. Moss A.R. and Bacchetti P. Natural history of HIV infection. AIDS. 1989; 3:55-61.
33. Rezza G., Lazzarin A., Angarano G., et al. The natural history of HIV infection in intravenous drug users, risk of disease progression in a cohort of seroconverters. AIDS. 1989; 3:87-90.
34. Kaplan J.E., Hanson D., Dworkin M.S., et al. Epidemiology of human immunodeficiency virus - associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2000; 30: S4-S14
35. Sacktor N., Lyles R.H., S. Kolasky R., et al. HIV- associated neurologic disease incidence changes: Multicentre AIDS Cohort Study 1990-1998. Neurol. 2001; 56:257-260.
36. Dilley J.W., Schwarcz S., Loeb L., et al. The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991-2003. AIDS. 2005; 19: 634-635.
37. Obel A.O.K., Sharif S.K., McLigeyo S.O., et al. Acquired immunodeficiency syndrome in an African. East Afr. Med. J. 1984; 61:724-726.
38. Moosa M.Y. and Coovachia Y.M. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings and outcome for human immunodeficiency virus (HIV) - positive and HIV-negative patients. Clin. Infect. Dis. 1997; 24:131-134.
39. Dore G.J., McDonald A., Li Y., et al. Marked improvement in survival following Aids dementia complex in the era of highly active anti-retroviral therapy. AIDS. 2003; 17:1539-1545.
40. Jowi J.O. Neurological manifestations of HIV infection and AIDS: A review. 2005. Ed. William Lore. Modern Litho graphics.
41. French N., Gray K., Waterac, et al. Cryptococcal infection of HIV-1 infected Ugandan adults. AIDS. 2002; 16:1031-1038.
42. Khanna N., Chandramuki., Desai A., et al. Cryptococcal infections of the central nervous system: An analysis of predis posing factors, laboratory findings and outcome in patients from South India with special reference to HIV infection.J. Med. Microbiol. 1996; 45:376-379.
43. Oyoo G.O. and Jowi J.O. Human immunodeficiency virus infection: Its prevalence and impact on morbidity and mortality in patients with meningitis at the Aga Khan Hospital, Nairobi, Kenya. Hlth. Line. 1998; 2: 27-29.
44. Hakim J.G., Gangaidzo I.T., Heyderman R.S., et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients. AIDS. 2000; 14:1401-1407.
45. Chuck S.L. and Sande M. A. Infections with cryptococcus neoformans in acquired immunodeficiency syndrome. N. Engl. J. Med. 1989; 321: 794-799.
46. Graybill J.R., Sobel J., Saag M., et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. 2000; 30:47-54.
47. Zuger A., Louie E., Holzman R.S., et al. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcomes of treatment. Ann. Intern. Med. 1986; 104:234-240.
48. Larsen RA, Leal MA, Chan LS. Fluconazole compared with Amphotericine-B plus flu cytosine for cryptococcal meningitis in AIDS a randomised trial. Ann. Intern. Med. 1990; 113:183-197.
49. Dismukes W.E., Cloud G., Gallis H.A., et al. Treatment of cryptococcal meningitis with combination Amphotericine-B and Flu cytosine for four as compared with six weeks. N. Engl. J. Med. 1992; 326:83-89.
50. Portegies P., Solod L., Cinque P., et al. Guidelines for the diagnosis and management of neurologic complications of HIV infection. Eur. J. Neurol. 2004; 11:297-304.
51. Leport C, Raffi F., Matheron S., et al. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with acquired immunodeficiency syndrome Amer. J. Med. 1988; 84:94-100.
52. Katlama C, Dewits, O'Doherty et al. Pyrimethamine - clindamycin vs. pyrimethamine-sulfadiazine in acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis. 1996a; 22:268-275. (Pubitemid 26056155)
53. Danneman Bv McCutchan J.A., Israelski D., et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomised trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California collaborative treatment group. Ann. Intern. Med. 1992; 116:33-43.
54. Thwaites G.E., Chau T.T., Stepniewka K., et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet. 2002; 360:1287-1292.
55. Whitley R.J. Herpes simplex virus infrctions of the central nervous system: A review. A.M.J. Med. 1988; 85: 61-67.
56. Kohl S. and James A.R. Herpes simplex virus encephalitis during childhood: importance of brain biopsy diagnosis. J. Pediatr. 1985; 107:212-215.
57. AIDS epidemic update 2004; Geneva: UNAIDS/ WHO.
58. Matthias M., Oliver K., Stefan E., et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J. Neurol. Neurosurg. Psychiat. 2000; 69:376-380.